Results 1 to 10 of about 707 (123)
Heart transplantation for Chagas cardiomyopathy
Revista Portuguesa de Cardiologia, 2017 Chagas disease is an endemic disease in Latin America that is increasingly found in non-endemic areas all over the world due to the flow of migrants from Central and South America.
Ana Rita Ramalho +4 more
doaj +5 more sources
Circulating microRNAs as biomarkers of Chagas cardiomyopathy
Frontiers in Cardiovascular Medicine, 2023 BackgroundChagas cardiomyopathy (CHCM) is the most important clinical manifestation of Chagas disease. The analysis of cardiac miRNAs may contribute to predicting the progression to CHCM in Chagas indeterminate phase and/or to the differential diagnosis ...
Laura Antonietti +13 more
doaj +4 more sources
Biomakers in Chronic Chagas Cardiomyopathy
Microorganisms, 2022 The primary objective was to observe the relationship between serum levels of BNP, Ca-125, C-reactive protein and uric acid as prognostic and functional markers in patients with chronic Chagas cardiomyopathy (CCC). Circulating levels of cytokines: IL-1β, TNFα, IL-10, IL6, IL-8 and IL-12 were determined and investigated regarding their association with ...
Maria Do Carmo Pereira Nunes +2 more
exaly +4 more sources
Autopsy and Case Reports, 2015 First described by Carlos Justiniano Ribeiro Chagas (1879-1934) in 1909, Chagas disease (CD) or American trypanosomiasis is caused by the protozoan parasite Trypanosoma cruzi.
Vera Demarchi Aiello +1 more
doaj +4 more sources
Chagas Disease Cardiomyopathy: Immunopathology and Genetics [PDF]
Mediators of Inflammation, 2014 Chagas disease, caused by the protozoan Trypanosoma cruzi, is endemic in Latin America and affects ca. 10 million people worldwide. About 30% of Chagas disease patients develop chronic Chagas disease cardiomyopathy (CCC), a particularly lethal ...
Edecio Cunha-Neto, Christophe Chevillard
doaj +3 more sources
Clinical Presentations of Chagas Cardiomyopathy
Case Reports in Cardiology, 2020 Chronic Chagas cardiomyopathy (CCC) is the most common cause of nonischemic cardiomyopathy in endemic Latin American countries. Immigrants to the United States suffer from this disease, but it is underrecognized.
Malik Shehadeh, Ana Barac, Rachel Marcus
doaj +3 more sources
Randomized Trial of Benznidazole for Chronic Chagas’ Cardiomyopathy
New England Journal of Medicine, 2015 The role of trypanocidal therapy in patients with established Chagas' cardiomyopathy is unproven.We conducted a prospective, multicenter, randomized study involving 2854 patients with Chagas' cardiomyopathy who received benznidazole or placebo for up to 80 days and were followed for a mean of 5.4 years. The primary outcome in the time-to-event analysis
Felipe Guhl +2 more
exaly +4 more sources
Stroke in Chagas disease: from pathophysiology to clinical practice [PDF]
Revista da Sociedade Brasileira de Medicina Tropical, 2022 Despite substantial progress toward its control, Chagas disease continues to be a major public health problem in Latin America and has become a global health concern.
Thaís Aparecida Reis Lage +6 more
doaj +1 more source
Autoantibodies in Chagas' Cardiomyopathy and Arrhythmias
Autoimmunity, 2001 Pablo A Chiale
exaly +3 more sources
Determinants of minute ventilation-carbon dioxide production relationship in Chagas cardiomyopathy
Revista da Sociedade Brasileira de Medicina Tropical, 2021 INTRODUCTION: The minute ventilation-carbon dioxide production relationship (VE/VCO2 slope) is among the main prognostic factors of Chagas cardiomyopathy whose determinants remain unknown. METHODS: Seventy-eight patients with Chagas cardiomyopathy were
Lucas Frois Fernandes Oliveira +9 more
doaj +1 more source